Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.

Yuki Kawana,Hiroaki Kamijo,Tomomitsu Miyagaki,Hiraku Suga,Shinichi Sato,Makoto Sugaya

doi:10.3390/ijms222212576

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS), the most common types of cutaneous T-cell lymphoma (CTCL), are characterized by proliferation of mature CD4+ T-helper cells. Patients with advanced-stage MF and SS have poor prognosis, with 5-year survival rates of 52%. Although a variety of systemic therapies are currently available, there are no curative options for such patients except for stem cell transplantation, and thus the treatment of advanced MF and SS still remains challenging. Therefore, elucidation of the pathophysiology of MF/SS and development of medical treatments are desired. In this study, we focused on a molecule called OX40. We examined OX40 and OX40L expression and function using clinical samples of MF and SS and CTCL cell lines. OX40 and OX40L were co-expressed on tumor cells of MF and SS. OX40 and OX40L expression was increased and correlated with disease severity markers in MF/SS patients. Anti-OX40 antibody and anti-OX40L antibody suppressed the proliferation of CTCL cell lines both in vitro and in vivo. These results suggest that OX40–OX40L interactions could contribute to the proliferation of MF/SS tumor cells and that the disruption of OX40–OX40L interactions could become a new therapeutic strategy for the treatment of MF/SS.

Highlights

Mycosis fungoides (MF) and Sézary syndrome (SS), the most common types of cutaneous T-cell lymphoma (CTCL) [1], are characterized by proliferation of mature CD4+T-helper cells [2]
Had higher OX40 and OX40 ligand (OX40L) mRNA levels compared to healthy subjects (Figure 1B)
OX40 and OX40L mRNA expression levels positively correlated with serum levels of soluble IL-2 receptor in MF/SS patients (Figure 1C)

Summary

Introduction

Mycosis fungoides (MF) and Sézary syndrome (SS), the most common types of cutaneous T-cell lymphoma (CTCL) [1], are characterized by proliferation of mature CD4+. MF typically presents in the form of skin patches and/or plaques, which can progress to skin tumors, with subsequent involvement of lymph nodes, peripheral blood, and visceral organs. In some MF cases, skin lesions become confluent and develop into erythroderma without blood involvement. SS is defined by the triad of generalized erythroderma, lymphadenopathy, and circulating atypical T cells [1]. Patients with advanced stage MF/SS have poor prognosis, and currently, there is no curative treatment for these patients [3]. Treatment is performed according to the stage, and the main treatments for early

Objectives

Results

Conclusion